EP
MRNA icon

Edgestream Partners’s Moderna MRNA Stock Holding History

Edgestream Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$267K Sell
5,254
-28,698
-85% -$1.34M 0.01% 817
2025
Q4 		$1M Sell
33,952
-88,227
-72% -$2.4M 0.03% 696
2025
Q3 		$3.16M Buy
122,179
+21,449
+21% +$598K 0.09% 403
2025
Q2 		$2.78M Buy
100,730
+2,769
+3% +$72.9K 0.08% 454
2025
Q1 		$2.78M Buy
97,961
+71,544
+271% +$2.54M 0.09% 402
2024
Q4 		$1.1M Sell
26,417
-19,869
-43% -$950K 0.05% 545
2024
Q3 		$3.09M Buy
46,286
+32,202
+229% +$2.96M 0.14% 261
2024
Q2 		$1.67M Buy
+14,084
New +$1.78M 0.08% 389
2024
Q1 		– Sell
-11,088
Closed -$1.1M – 946
2023
Q4 		$1.1M Buy
+11,088
New +$933K 0.08% 415
2022
Q4 		– Sell
-2,040
Closed -$241K – 589
2022
Q3 		$241K Buy
+2,040
New +$310K 0.02% 416

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Edgestream Partners's MRNA Position: Q1 2026 in Review

Edgestream Partners reduced its Moderna (MRNA) stake by 85% in Q1 2026, selling an estimated $1.34M and leaving 5,254 shares worth $267K. The position accounts for 0.01% of the portfolio, ranked #817.

Edgestream Partners first reported a position in MRNA in Q3 2022 and has held it in 10 quarters since. The position peaked at $3.16M in Q3 2025. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Edgestream Partners held 5,254 shares of Moderna worth $267K as of Q1 2026.
  • Edgestream Partners sold 28,698 Moderna shares in Q1 2026, an estimated $1.34M.
  • Moderna made up 0.01% of Edgestream Partners's portfolio in Q1 2026, its #817 holding.
  • Edgestream Partners first reported a position in Moderna in Q3 2022 and has held it in 10 quarters since.
  • Edgestream Partners's Moderna position peaked at $3.16M in Q3 2025.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Edgestream Partners's 13F filing for Q1 2026, filed 18 May 2026.